These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 30899983)

  • 1. Placental growth factor is a predictive biomarker for ramucirumab treatment in advanced gastric cancer.
    Natsume M; Shimura T; Iwasaki H; Okuda Y; Kitagawa M; Okamoto Y; Hayashi K; Kataoka H
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1037-1046. PubMed ID: 30899983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer.
    Okunaka M; Kotani D; Demachi K; Kawazoe A; Yoshino T; Kawasaki T; Shitara K
    BMC Cancer; 2020 Nov; 20(1):1111. PubMed ID: 33198652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective comparison of nab-paclitaxel plus ramucirumab and paclitaxel plus ramucirumab as second-line treatment for advanced gastric cancer focusing on peritoneal metastasis.
    Ishikawa M; Iwasa S; Nagashima K; Aoki M; Imazeki H; Hirano H; Shoji H; Honma Y; Okita N; Takashima A; Kato K; Saruta M; Boku N
    Invest New Drugs; 2020 Apr; 38(2):533-540. PubMed ID: 31264067
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ramucirumab Beyond Disease Progression After Paclitaxel Plus Ramucirumab in Gastric Cancer: A Phase II Trial.
    Sato Y; Yamashita H; Yagi K; Nomura S; Seto Y
    Anticancer Res; 2024 Jul; 44(7):3125-3131. PubMed ID: 38925825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nanoparticle albumin-bound paclitaxel and ramucirumab versus paclitaxel and ramucirumab as second-line chemotherapy for unresectable advanced or recurrent gastric cancer: a multicenter, propensity score-matched analysis (CROSS SELL study).
    Nakasya A; Hagiwara Y; Ikoma T; Kurioka Y; Matsumoto T; Yamamoto Y; Tsuduki T; Kajiwara T; Moriwaki T; Nishina T; Yamashita N; Hyodo I
    Int J Clin Oncol; 2022 Apr; 27(4):684-694. PubMed ID: 35089459
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical usefulness of ramucirumab plus paclitaxel for unresectable and recurrent gastric cancer.
    Hayase S; Yamada L; Ujiie D; Nirei A; Tada T; Hanayama H; Monma T; Saze Z; Ohki S; Kono K
    Fukushima J Med Sci; 2019; 65(1):6-12. PubMed ID: 30996218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarker analyses of second-line ramucirumab in patients with advanced gastric cancer from RAINBOW, a global, randomized, double-blind, phase 3 study.
    Van Cutsem E; Muro K; Cunningham D; Bodoky G; Sobrero A; Cascinu S; Ajani J; Oh SC; Al-Batran SE; Wainberg ZA; Wijayawardana SR; Melemed S; Ferry D; Hozak RR; Ohtsu A;
    Eur J Cancer; 2020 Mar; 127():150-157. PubMed ID: 32014812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of peripheral neuropathy induced by platinum in first-line chemotherapy on second-line chemotherapy with paclitaxel for advanced gastric cancer.
    Otsuka R; Iwasa S; Yanai T; Hirano H; Shoji H; Honma Y; Okita N; Takashima A; Kato K; Hashimoto H; Sekiguchi M; Makino Y; Boku N; Yamaguchi M
    Int J Clin Oncol; 2020 Apr; 25(4):595-601. PubMed ID: 31853798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trial.
    Di Bartolomeo M; Niger M; Morano F; Corallo S; Antista M; Tamberi S; Lonardi S; Di Donato S; Berardi R; Scartozzi M; Cardellino GG; Di Costanzo F; Rimassa L; Luporini AG; Longarini R; Zaniboni A; Bertolini A; Tomasello G; Pinotti G; Scagliotti G; Tortora G; Bonetti A; Spallanzani A; Frassineti GL; Tassinari D; Giuliani F; Cinieri S; Maiello E; Verusio C; Bracarda S; Catalano V; Basso M; Ciuffreda L; De Vita F; Parra HS; Fornaro L; Caporale M; de Braud F; Pietrantonio F
    BMC Cancer; 2019 Mar; 19(1):283. PubMed ID: 30922323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Implications of Decreased Computed Tomography Value after Ramucirumab in Advanced Gastric Cancer.
    Izawa N; Sunakawa Y; Doi A; Arai H; Horie Y; Hirakawa M; Mizukami T; Ogura T; Tsuda T; Nakajima TE
    Oncology; 2019; 97(2):94-101. PubMed ID: 31195391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness and safety of ramucirumab plus paclitaxel chemotherapy in the treatment of advanced and recurrent gastric cancer.
    Kimura M; Usami E; Teramachi H; Yoshimura T
    J Oncol Pharm Pract; 2018 Sep; 24(6):403-411. PubMed ID: 28436252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The Clinical Effect of Ramucirumab in the Treatment of Advanced Gastric Cancer in Our Hospital].
    Kenno S; Takahashi S; Noguchi K; Yamagami H; Ishizu H; Takahashi M
    Gan To Kagaku Ryoho; 2018 Jan; 45(1):79-81. PubMed ID: 29362314
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Second-line Chemotherapy on Prognosis: Response of Advanced Gastric Cancer to Taxanes Plus Ramucirumab.
    Masuda Y; Kananazawa Y; Matsuno K; Kakinuma D; Sakurazawa N; Ando F; Hagiwara N; Nomura T; Kato S; Yoshiyuki T; Yoshida H
    Anticancer Res; 2022 Mar; 42(3):1599-1605. PubMed ID: 35220257
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites.
    Matsumoto H; Kawazoe A; Shimada K; Fukuoka S; Kuboki Y; Bando H; Kojima T; Ohtsu A; Yoshino T; Doi T; Shitara K
    BMC Cancer; 2018 Jan; 18(1):120. PubMed ID: 29385993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.
    Vahdat LT; Layman R; Yardley DA; Gradishar W; Salkeni MA; Joy AA; Garcia AA; Ward P; Khatcheressian J; Sparano J; Rodriguez G; Tang S; Gao L; Dalal RP; Kauh J; Miller K
    Oncologist; 2017 Mar; 22(3):245-254. PubMed ID: 28220020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical Experience of Ramucirumab for Treating Advanced Gastric Cancer].
    Kimura Y; Makari Y; Mikami J; Kamigaki S; Ikejima A; Fujii C; Sawada G; Nakahira S; Yamamura J; Nakata K; Yamamoto T; Ikeda N; Tsujie M; Fujita J; Ohzato H
    Gan To Kagaku Ryoho; 2016 Oct; 43(10):1193-1196. PubMed ID: 27760936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ramucirumab for Treating Advanced Gastric Cancer or Gastro-Oesophageal Junction Adenocarcinoma Previously Treated with Chemotherapy: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Büyükkaramikli NC; Blommestein HM; Riemsma R; Armstrong N; Clay FJ; Ross J; Worthy G; Severens J; Kleijnen J; Al MJ
    Pharmacoeconomics; 2017 Dec; 35(12):1211-1221. PubMed ID: 28656543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and efficacy of ramucirumab in combination with paclitaxel for the treatment of advanced gastric or gastro-esophageal junction adenocarcinoma.
    Garrido M
    Expert Rev Anticancer Ther; 2016 Oct; 16(10):1005-10. PubMed ID: 27582051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8
    Tada Y; Togashi Y; Kotani D; Kuwata T; Sato E; Kawazoe A; Doi T; Wada H; Nishikawa H; Shitara K
    J Immunother Cancer; 2018 Oct; 6(1):106. PubMed ID: 30314524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Placental growth factor neutralising antibodies give limited anti-angiogenic effects in an in vitro organotypic angiogenesis model.
    Brave SR; Eberlein C; Shibuya M; Wedge SR; Barry ST
    Angiogenesis; 2010 Dec; 13(4):337-47. PubMed ID: 20953695
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.